Ultragenyx Pharmaceutical Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Ultragenyx Pharmaceutical Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$116M, a 21.4% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$549M, a 18.4% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2023 was -$569M, a 12.3% increase from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2022 was -$649M, a 70% decline from 2021.
  • Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2021 was -$382M, a 15.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$569M +$79.7M +12.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 -$649M -$267M -70% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 -$382M -$51.6M -15.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$330M +$94.1M +22.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 -$424M -$52.8M -14.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$371M -$42.4M -12.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 -$329M -$80.9M -32.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 -$248M -$100M -67.9% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-20
2015 -$148M -$91M -160% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-21
2014 -$56.8M -$24.5M -75.9% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
2013 -$32.3M -$16.3M -102% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 -$16M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.